In an effort to probe the inhibition of glyoxalase II (GLX2-2) from Arabidopsis thaliana, a series of N -and S-blocked glutathione compounds containing 9-fluorenylmethoxycarbonyl (FMOC) and Cbz protecting groups were synthesized and tested. The di-FMOC and di-Cbz compounds were the best inhibitors of GLX2-2 with K i values of 0.89 AE 0.05 and 2.3 AE 0.5 lM, respectively. The removal of protecting groups from either position resulted in comparable, diminished binding affinities. Analyses of site-directed mutants of GLX2-2 demonstrated that tight binding of these inhibitors is not due to interactions of the protecting groups with hydrophobic amino acids on the surface of the enzyme. Instead, MM2 calculations predict that the lowest energy structures of the unbound, doubly substituted inhibitors are similar to those of a bound inhibitor. These studies represent the first systematic attempt to understand the peculiar inhibition of GLX2 by N -and S-blocked glutathiones.
The ubiquitous glyoxalase (GLX) 1 system appears to be involved in cellular detoxification by catalyzing the conversion of cytotoxic and mutagenic 2-oxoaldehydes into hydroxyacids using glutathione (GSH) as a cofactor [1] . The glyoxalase system is made up of two enzymes: glyoxalase I (GLX1), which is a Zn(II)-or Ni(II)-dependent enzyme that isomerizes the equilibrium adduct of methylglyoxal and glutathione to form S-D Dlactoylglutathione (SLG) [2, 3] , and glyoxalase II (GLX2), which is a Fe-and Zn-containing enzyme that catalyzes the hydrolysis of the thioester to liberate D Dlactic acid and regenerate GSH [4, 5] . Previous studies have implicated the glyoxalase system in cell cycle control, cancer, malaria, and diabetes, and inhibitors of GLX1 and GLX2 have been designed as antiprotozoal and antitumor agents [6] [7] [8] [9] [10] [11] [12] [13] .
A large amount of information on the structure and reaction mechanism of GLX1, of which there is only one isozyme in most organisms, is available [2, 3, 9, [13] [14] [15] [16] [17] . Considerably less is known about the mechanism and structure of GLX2, which has been isolated from a number of sources. It has also been cloned and purified from humans and Arabidopsis thaliana [18] [19] [20] . Complicating the issue further, there are multiple isozymes of GLX2 in plants and animals. For example, there are five putative GLX2 isozymes in Arabidopsis [20] . [21] demonstrated that GLX2 is a Zn(II)-dependent enzyme and predicted that GLX2 has a dinuclear Zn(II) binding site similar to those in the metallo-b-lactamases. A crystal structure of human GLX2, which was subsequently reported [22] , showed that the enzyme has a dinuclear Zn(II) center that is similar to the metal binding site of metallo-b-lactamase L1 from Stenotrophomonas maltophilia [23] and that GLX2 belongs to the class of Zn(II) metallohydrolases with a b-lactamase fold [24] . However, Zang et al. [5] have recently shown that GLX2-2 from A. thaliana may be a dinuclear FeZn metalloenzyme, reminiscent of certain plant purple acid phosphatases [25] .
Several GLX2 inhibitors such as N,S-bis-9-fluorenylmethoxycarbonyl (FMOC) glutathione (D F G; 1, K i values 0.08-320 lM; Fig. 1 ) [8, 26, 27] and S-phenylmethoxycarbonylglutathione (S-Cbz-glutathione or Z S G, 2, K i values 13-88 lM) [28] [29] [30] [31] have been reported in the literature. However, inhibition studies on GLX2 from different sources often have resulted in inconsistent or contradictory findings. For example, in different studies the bulky N,S-linked glutathione derivative 1 (D F G) was reported to be a competitive inhibitor of calf liver GLX2 with a K i of 80 or 750 nM [8, 26] . The S-FMOC glutathione derivative 3 was also reported to inhibit GLX2 from A. vera with a K i of 4.6 lM [28] . Therefore, it has been difficult to utilize this information to understand how the enzymes initially interact with different substrates and elucidate the reaction mechanism of the enzyme.
The structure of human GLX2 with bound glutathione and bound S-(N -hydroxy-N -bromophenylcarbamoyl)glutathione (HBPCG, 4) (Fig. 2) , a competitive inhibitor [32] , showed significant enzyme-glutathione interactions, particularly with the carboxy terminus and thiol of glutathione [22] . In addition, there was significant contact between the enzyme and the S-linked substituent. Al-Timari and Douglas [31] have hypothesized that the N terminus of glutathione (and substituents attached to the N terminus) makes no contacts with GLX2, and the crystal structure of human GLX2 appears to support this hypothesis [22] . Nonetheless, the relatively tight binding of glutathione derivatives with bulky hydrophobic substituents is somewhat surprising. It is also difficult to reconcile the reported tight binding of D F G to calf liver GLX2 (K i values of 80-750 nM) [8, 26] compared to the relatively weaker binding of the S-FMOC glutathione derivative (K i value of 2.1 lM). Moreover, there are no glutathione compounds, that contain substituents only on the N terminus of glutathione that can be used to test this hypothesis directly. Therefore, we conducted a systematic study to address (1) which substituents on the inhibitor are essential for tight binding, (2) whether the FMOC substituent is essential for tight binding, (3) whether hydrophobic interactions contribute to the tight binding of D F G, and (4) whether entropic effects explain the tight binding of D F G. This paper also describes the synthesis of four new N -linked glutathione derivatives, which for the first time allow for the evaluation of the N -linked substituentÕs role in binding. A better understanding of how these inhibitors bind allows for their use in characterization of GLX2 isozymes and mutants and provides insights into factors important for substrate and inhibitor binding. 
Materials and methods

General
All synthetic reagents were purchased from Aldrich. Reaction progress was monitored with thin-layer chromatography on Kodak 13181 silica gel sheets with fluorescent indicator. Column chromatography was carried out on Aldrich 60-A A 70-230 mesh silica gel using the solvent systems listed.
1 H NMR spectra were obtained with Bruker AMX-200 or AMX-300 spectrometers.
1 H NMR chemical shifts were recorded in parts per million (ppm), relative to tetramethylsilane as the internal reference. D F G 1, Z S G 2, F S G 3, and D Z G 6 were prepared as described previously [26, 30, 31, 33] . Mass spectra (E.S.I.) were collected at the Campus Chemical Instrumentation Center at Ohio State University, and elemental analyses (C, H, N) were performed at Galbraith Laboratories.
To a solution of 0.92 g (0.30 mmol) of glutathione dissolved in 15 ml of 10% NaHCO 3 and 5 ml of dioxane was added under a nitrogen atmosphere a solution of 0.79 g (3.0 mmol) 9-fluorenylmethyl chloroformate in 10 ml of dioxane. The mixture was stirred at room temperature for 3 h, poured into 250 ml of H 2 O, and extracted with ether to remove small amounts of 9-fluorenylmethanol. The aqueous layer was cooled and acidified with concentrated HCl to pH 3.5. The resulting precipitate was extracted with ethyl acetate, and the combined extracts were washed with water, dried over MgSO 4 , and evaporated to give 1.37 g (85%) of the title compound. TLC analysis (10% ethyl acetate/methanol) gave a single, KMnO 4 -clear yellow spot; R f ¼ 0:81. The pure F N G gave a positive test for the presence of SH groups [34] . 1 
Glutathione (1.23 g, 4.0 mmol) was added to 5 ml of 2 N NaOH containing 0.67 g (8 mmol) of NaHCO 3 and 0.8 g (8.0 mmol) of Na 2 CO 3 . After the mixture was cooled in an ice water bath, 0.6 ml (4.1 mmol) of benzyl chloroformate (Cbz-Cl) was added slowly by syringe. Two additional 4.1-ml portions of Cbz-Cl were added at 1-h intervals. After the reaction mixture was stirred overnight, 1 ml of 2 N NaOH and 10 ml of water were added. This solution was extracted twice with ether and then acidified with concentrated HCl. The milky solution was extracted three times with EtOAc, and the organic layers were combined, washed with brine, dried, and evaporated to give 1.25 g of the desired compound as white solid in 71% yield. The pure Z N G gave a positive test for the presence of SH groups [34] . 1 
A solution of 0.6 g (2.61 mmol) of 9-fluorenylmethyl chloroformate (FMOC-Cl) in 10 ml of dioxane was slowly added to a solution of 10.5 g (2.61 mmol) Z S G, 2, in 10 ml of 10% Na 2 CO 3 that was cooled in an ice bath. The mixture was stirred at room temperature for 5 h, diluted with 120 ml of water, and extracted twice with ether to remove small amounts of unreacted FMOC-Cl. The aqueous layer was cooled and acidified with concentrated HCl to pH 2, and the resulting white precipitate was redissolved in 2 ml of DMSO. The desired product was precipitated by the addition of cold water. The white solid was filtered, washed with water and ethanol, and dried to give 0.89 g (yield 51%) of 8. 
The product 7 described above (1.02 g, 2.3 mmol) was dissolved in a cold solution of acetone (12 ml) and water (15 ml) containing 0.58 g (6.9 mmol) of NaHCO 3 . After the reaction mixture was stirred for 10 min, 0.95 g (2.8 mmol) of 9-fluorenylmethyl N -succinimidyl carbonate was added, and the mixture was stirred at 4°C for 2 days. A white precipitate was removed by filtration, the filtrate was acidified to pH 2, and the resulting precipitate was washed with cold water, ethanol, and ether and dried to give 0.87 g of the title compound as white solid in 57% yield. 1 
Assays of GLX2-2 with inhibitors
Recombinant wild type GLX2-2 from A. thaliana was overexpressed and purified as described previously [5] . The activity of GLX2-2 from A. thaliana was assayed by measuring the initial rate of hydrolysis of S-D D -lactoylglutathione to yield reduced glutathione and D D -lactic acid in 10 mM Mops, pH 7.2, at 25°C using either a HP5483 Diode Array UV-Vis Spectrophotometer or a Cary 1E UV-Vis Spectrophotometer. The rate of hydrolysis was followed by measuring the absorbance at 240 nm and by using the molar absorptivity of the substrate (e 240 ¼ À3100 L/mol cm). The observed hydrolysis rates were corrected for any background hydrolysis (in the absence of the enzyme) at each substrate concentration tested. Substrate concentrations were varied between 15 and 600 lM, but concentrations higher than 600 lM were not used due to substrate inhibition. Stock solutions of 8 and 9 were made by dissolving them in MeOH and diluting the stock solution 1:10 with 10 mM Mops, pH 7.2. The concentrations used in the inhibition studies varied between 1.0 and 15 lM D F G. All of the remaining compounds were dissolved in DMSO, and the stock solutions were diluted with 10 mM Mops, pH 7.2, to the desired concentrations. The modes of inhibition were determined by generating Lineweaver-Burk plots of the data, and the K i values for the inhibitors were determined by fitting initial velocity versus substrate concentration at each inhibitor concentration to v i ¼ V max ½S=ð½S þ K m ð1 þ ½I=K i ÞÞ using SigmaPlot v. 4.0, where v i is initial velocity, V max is maximum velocity, ½S is initial substrate concentration, K m is Michaelis constant, ½I is inhibitor concentration, and K i is inhibition constant.
Site-directed mutants of GLX2-2
Site-specific mutations were introduced into GLX2-2 by using a previously reported procedure [5] . The numbering of amino acids corresponds to the Arabidopsis GLX2-2 sequence (GenBank Accession No. O24496). The nondegenerate oligonucleotides used for mutagenesis were L9AFOR, ACGTTCCTTGTGCGCAAGAC AACTAC; L9AREV, GTAGTTGTCTTGCGCACAA GGAACGT; W57DFOR, GCATCATCACGATGATC ATGCCGGTGG; W57DREV, TCCACCGGCATGAT CATCGTGATGATG; W57NFOR, GCATCATCACA CCGATCATGCCGGTGGA; W57NREV, TCCACCG GCATGATCGGTGTGATGATGC; K65AFOR, TGG AAACGAGGCGATTAAGCAGTTGGTTC; and K65 AREV, GAACCAACTGCTTAATCGCCTCGTTTC CA. The correct gene sequences were ascertained using an ABI Prism Automated Sequencing System from Perkin-Elmer. The GLX2-2 mutants were overexpressed and purified as previously reported [5, 21] . Metal content of the mutants was ascertained using a Perkin-Elmer inductively coupled plasma spectrometer with atomic emission detection (ICP-AES).
MM2 calculations of the inhibitors
MM2 calculations on the N -and S-linked glutathiones were conducted using the Chem3D Pro software (version 4) using the manufacturerÕs software instructions. The lowest energy structures were determined by starting energy minimizations on at least 10 different starting structures.
Results and discussion
N-and S-blocked glutathione derivatives as inhibitors of A. thaliana GLX2
Inhibitor studies can often provide insight into the structures and reaction mechanisms of enzymes. However, because of the sometimes confusing and conflicting data in the literature concerning GLX2 inhibitors, it has been difficult to use this information to help gain insight into substrate binding to and the enzyme mechanisms of GLX2. Described below are the results of experiments on Arabidopsis GLX2-2 designed to better understand important factors in D F G binding to GLX2.
Previous inhibition studies using D F G were conducted on GLX2 purified from calf liver [8, 26] and Aloe vera [27] ; however, the K i values reported differed by several orders of magnitude. To determine whether D F G inhibits GLX2 from A. thaliana, the di-FMOC compound, D F G 1, was synthesized as previously described [26] and tested as an inhibitor of cytosolic GLX2 (GLX2-2) from A. thaliana [20] . D F G was found to be a competitive inhibitor of the Arabidopsis enzyme with a K i value of 0.89 AE 0.05 lM (Table 1) . This value is similar to that in the first report on the calf liver enzyme [8] and confirms that D F G binds much tighter to Arabidopsis GLX2 than does glutathione (Table 1 ) [5] .
To evaluate how each FMOC group contributes to binding, we synthesized glutathione derivatives containing single FMOC groups at the N terminus (F N G, 5) and at the thiol group (F S G, 3) [33] , and the compounds were tested as inhibitors of A. thaliana GLX2-2. F N G and F S G were shown to be competitive inhibitors with K i values of 15.2 and 14.2 lM, respectively, representing a ca. 16-fold decrease in binding affinity as compared to the di-FMOC glutathione 1 (Table 1) . Clearly, two FMOC groups must be present for tight binding of the FMOC-linked glutathione derivatives to GLX2-2. In contrast to an earlier hypothesis that only the S-linked FMOC is important in binding [31] , our results show that the loss of either FMOC results in significantly weaker binding.
To test whether the tight binding of the FMOCcontaining glutathione derivatives is specifically due to the FMOC groups, we synthesized glutathione derivatives containing Cbz protecting groups. The di-Cbz compound, D Z G 6, and the S-linked Cbz derivative, Z S G 2, were synthesized as previously reported [30, 31] . The N -linked Cbz derivative, Z N G 7, was synthesized as described under Materials and methods. Although exhibiting weaker binding than D F G, D Z G was shown to be a competitive inhibitor with a K i of 2.3 lM (Table 1) . This K i value is similar to those reported previously when the calf liver and A. vera GLX2 enzymes were used [28, 31] . The loss of either Cbz group resulted in weaker binding of the resulting mono-Cbz-containing glutathione derivative (Z S G, K i ¼ 4:9 lM, Z N G, K i ¼ 5:6 lM); however, the relative magnitude of the drop in affinity is less for the Cbz-containing compounds than for the FMOC-containing compounds. Initially, we hypothesized that the relatively tighter binding of the doubly blocked inhibitors was due to interactions of the substituents with hydrophobic amino acids remote from the active site; i.e., two FMOC groups would interact with two separate groups on the enzyme and increase the binding of D F G to GLX2.
Site-directed mutants of A. thaliana GLX2
Although a crystal structure of D F G bound to GLX2 has not been reported, the structure of HBPCG bound to human GLX2 (Fig. 2) potentially offers insight into binding of the di-FMOC derivative 1. The structure of human GLX2 with bound HBPCG 4 showed that the S-linked bromophenyl group is completely accessible to solvent; however, there is a hydrophobic contact with His56, and the carbonyl of the S-hydroxybromophenyl carbamoyl group interacts with Zn1 [22] . This additional contact of HBPCG may account for the increased affinity of HBPCG with GLX2, as compared to glutathione [5] . The crystal structure also showed that the N terminus of HBPCG points away from the active site toward a hydrophobic surface area made up of Leu9, Trp57, and Lys65 [22] , which are strictly conserved in the human and the A. thaliana GLX2 enzymes [20] . Extrapolating the binding of HBPCG to the di-FMOC derivative 1, we speculated that the S-linked FMOC (or Cbz) group may interact with His56 and that the N -linked FMOC (or Cbz) may interact with Leu9, Trp57, and/or Lys65 and thereby increase binding affinity.
Our previous mutagenesis studies on GLX2-2 showed that mutations of metal binding ligands result in enzymes that cannot be purified in a soluble form [5] . Therefore, it was not possible to directly test the hydrophobic contact of the S-linked substituent with His56. However, we could test whether the increased binding of the glutathione derivatives with N -linked substituents was due to hydrophobic contacts with Leu9, Trp57, or Lys65. The L9A, W57N, W57D, and K65A mutants of GLX2-2 were prepared and characterized for inhibition by D F G ( Table 2 ). All four mutants were overexpressed and purified at levels comparable to those of wild-type GLX2-2. Each of the Table 2 Inhibition studies with D F G on GLX2 mutants Table 2 ). D F G is a competitive inhibitor of all four mutants, and surprisingly, the K i value for all mutants was ca. 2.5 lM. This decreased binding affinity accounts for only ca. 0.6 kcal/mole (DDG o0 ). Although D F G did bind more weakly to all four mutants as predicted, none of the mutants exhibited a K i value as high as that of F S G (14.2 lM, DDG o0 ¼ 1:6 kcal/mole). In addition, the W57D mutant with a negative charge in the binding pocket was expected to result in significantly weaker binding. However, the K i exhibited by the W57D mutant was statistically identical to that exhibited by the other mutants (Table 2) . Therefore, the increased binding affinity of D F G and D Z G, as compared to glutathione or S-linked compounds, cannot be attributed to hydrophobic interactions between the N -linked FMOC and the conserved amino acid residues on the surfaces of human and A. thaliana GLX2.
Binding affinity can be attributed to entropic events
Since the increased binding of the di-substituted glutathiones could not adequately be explained by interactions of the substituents with hydrophobic areas on the enzyme, we hypothesized that the substituents could interact and constrain the average conformation of the glutathionyl backbone of the unbound inhibitor to be more like that of the bound inhibitor. The larger FMOC groups would be better at constraining this conformation, accounting for the increased binding affinity of D F G as compared to D Z G. Support for this argument is provided by the crystal structures of human GLX2 bound to HBPCG and glutathione (Fig. 3) . As mentioned earlier, when HBPCG is bound in the active site, the N terminus of glutathione points toward Leu9, Trp57, and Lys65. In addition, the N-terminal substituent points toward the S-linked substituent, allowing the S-and N -linked FMOC groups to stack when D F G is bound in the active site. The p-stacking of FMOC groups would also be favored when D F G is unbound. A different picture is observed when glutathione is bound in the active site of human GLX2; the N terminus points in a different direction due to rotation about the C5-N bond of glutathione (Fig. 3) .
To test this hypothesis, MM2 calculations were conducted on D F G, F N G, F S G, D Z G, Z N G, and Z S G (Fig. 4) . The lowest energy structure for D F G is shown in Fig. 4A . This structure shows the FMOC groups partially overlapping and the glutathione carboxyl group pointing away. Using the human GLX2 crystal structures with glutathione or HBPCG bound [22] and our previous mutagenesis data [5] , we hypothesized that the carboxyl terminus of the inhibitors must be able to fit in the deepest part of the active site. The lowest energy structure of D F G has very few steric problems between the carboxyl terminus and the FMOC groups, and interestingly, the glutathione backbone is similar to that of bound HBPCG (Figs. 3 and 4) . Structures of D F G that had the FMOC groups separated were significantly higher in energy. Similarily, the lowest energy structure of D Z G (Fig. 4B) had a shape similar to that of the D F G compound, with the benzyl groups directed toward each other. Structures with the Cbz groups pointing in different directions were significantly higher in energy. In contrast, there were little differences in the energies of the F N G, F S G, Z N G, or Z S G structures when the N -linked substitutents were pointed in the same direction or in the opposite direction as the Slinked substituents (data not shown). The larger FMOC groups on F N G and F S G likely cause more steric problems with the carboxyl terminus and result in weaker affinities of these compounds as compared with Z N G or Z S G. Taken together, the relative tight binding of the di-substituted glutathione derivatives, as compared to the singly substituted compounds or to free glutathione, appears to be due to the lower entropy barrier that the di-substituted compounds must overcome to reach the structure of the bound inhibitor.
Mixed protecting group glutathione inhibitors
To further test our prediction, glutathione analogs with mixed protecting groups were analyzed. The most obvious differences in the Cbz and FMOC substituents are the size and relative hydrophobicities of the protecting groups; therefore, we speculated that differences in inhibition properties between the Cbz-and the FMOC-containing compounds were due to the ability of the protecting groups to interact with each other. In other words, we expected that the FMOC-Cbz interaction would be weaker than that of the FMOC-FMOC interaction in D F G but stronger than the Cbz-Cbz interaction in D Z G. Therefore, we expected the K i values of the mixed protecting group containing glutathiones to be intermediate between those of the D F G and D Z G compounds.
The glutathione derivatives with mixed protecting groups were synthesized as described under Materials and methods. As expected, the N -linked FMOC, the Slinked Cbz derivative (F N Z S G, 8), and the S-linked FMOC, N -linked Cbz derivative (Z N F S G, 9) are competitive inhibitors of GLX2-2 with K i values of 1.7 and 2.0 lM, respectively. By using MM2 calculations, we were able to evaluate the lowest energy structures of 8 and 9, which are shown in Figs. 4C and D; these structures are similar to that of D F G (Fig. 4A) and show potential overlap of the FMOC and Cbz groups. Therefore, it appears that the nature of the protecting groups influences the conformation of the inhibitors in solution and ultimately the binding properties of the compounds.
Conclusions
This study provides the first systematic attempt to explain the unexpected inhibition of GLX2 by N -and Slinked glutathione compounds. While an as yet unidentified binding groove for the FMOC groups cannot be completely ruled out, these data suggest that the relatively tight binding of D F G to GLX2 is due to entropic events in which D F GÕs conformation is constrained by FMOC-FMOC interactions, and this constrained conformation is similar to D F G when bound to the enzyme. These studies allow for a more precise description of how the D F G molecule binds to GLX2 and reveal what inhibitor-enzyme interactions are essential for tight binding. Efforts to prepare D F G analogs that have the FMOCÕs covalently tethered (to further constrain the conformation of the compound) and N,S-linked glutathione derivatives with substituents larger and more hydrophobic than FMOC to further test this hypothesis will be made in the future.
